Hydrocortisone Reduces 28-day Mortality in Septic Patients: A Systemic Review and Meta-analysis

Waqq J. Siddiqui 1, 2, Praneet Iyer 3, Ghulam Aftab 4, FNU Zafirullah 5, Muhammad Zain 6, Kadambari Jethwani 7, Rabia Mazhar 8, Usman Abdul Salam 9, Abbas Raza 7, Muhammad O. Hanif 10, 7, Esha Sharma 11, Sandeep Aggarwal 10

1. Cardiology/Nephrology, Drexel University College of Medicine, Philadelphia, USA 2. Cardiology/Nephrology, Orange Park Medical Center, Orange Park, USA 3. Internal Medicine, University of Tennessee Health Sciences Center, Memphis, USA 4. Pulmonary Medicine, St. Peter’s University Hospital, New Brunswick, USA 5. Internal Medicine, Steward Carney Hospital, Tufts University School of Medicine, Boston, USA 6. Internal Medicine, Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, PAK 7. Internal Medicine, Drexel University, Philadelphia, USA 8. Internal Medicine, Orange Park Medical Center, Orange Park, USA 9. Internal Medicine, Steward Carney Hospital, Boston, USA 10. Nephrology, Drexel University, Philadelphia, USA 11. Internal Medicine, George Washington University, Washington D.C., USA

Corresponding author: Ghulam Aftab, gaftab@saintpetersuh.com

Abstract

The goal of this study was to determine the utility of hydrocortisone in septic shock and its effect on mortality. We performed a systematic search from inception until March 01, 2018, according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines comparing hydrocortisone to placebo in septic shock patients and selected studies according to our pre-defined inclusion and exclusion criteria. Four reviewers extracted data into the predefined tables in the Microsoft Excel (Microsoft Corp., New Mexico, US) sheet. We used RevMan software to perform a meta-analysis and draw Forest plots. We used a random effects model to estimate risk ratios. A two-sided p-value of ≤ 0.05 was considered statistically significant. A total of five randomized control trials (RCTs) with 5,838 patients were included in our analysis. The primary outcome was mortality at 28 days. Secondary outcomes were intensive care unit (ICU) and hospital length of stay, incidence of superinfections, and incidence of limb and/or cerebral ischemia. The 28-day mortality was significantly reduced with hydrocortisone, 808 vs. 880 with placebo, Risk Ratio (RR)=0.92, confidence interval (CI) -0.85-0.99, p=0.04, I²=0%. There was no difference in ICU mortality (RR=0.95, CI=0.81-1.08), in-hospital mortality (RR=0.95, CI=0.84-1.08), 90-day mortality (RR=0.93, CI=0.84-1.02, p=0.10), and one-year mortality (RR=0.97, CI=0.84-1.12). Superinfections were significantly common with hydrocortisone, RR=1.16, CI=1.05-1.28, p<0.005. In conclusion, the use of hydrocortisone showed a significant reduction in mortality at 28 days and a trend toward reduced ICU mortality. This mortality reduction was observed at the cost of significantly higher superinfections.

Keywords: hydrocortisone, sepsis, septic shock, fludrocortisone, mortality, meta-analysis

Introduction

Sepsis is a significant health concern globally with an associated mortality of 14.7% to 29.9% [1]. Over the years, although the number of sepsis cases and total mortality has increased, the associated case fatality rate has decreased [1]. Other than the respiratory support with mechanical ventilation, hemodynamic support has decreased [2]. The use of steroids was discouraged until 2002 when the French study by Annane et al. showed significant mortality benefit with the use of steroids, which brought steroids back in favor [9]. Several subsequent studies, including systematic reviews, meta-analysis, and randomized control trials (RCTs), have not shown consistent evidence for or against steroids in sepsis and septic shock [10-12]. Current surviving sepsis guidelines recommend the use of steroids when fluid resuscitation and vasopressors, and source control of the infection with antibiotics and surgical evacuation of infection, there is no additional approved treatment for either sepsis or septic shock.

A study from 1976 by Schum et al. showed a significant reduction in mortality in septic shock with high dose steroids given for a short duration [5]. However, several subsequent studies were unable to replicate these findings but, in turn, showed increased associated mortality due to a higher incidence of superinfection, defined as a new clinical infection that occurred during therapy or within ten days of discontinuation of antimicrobial agents [6-8]. The use of steroids was discouraged until 2002 when the French study by Annane et al. showed significant mortality benefit with the use of steroids, which brought steroids back in favor [9]. Several subsequent studies, including systematic reviews, meta-analysis, and randomized control trials (RCTs), have not shown consistent evidence for or against steroids in sepsis and septic shock. Current surviving sepsis guidelines recommend the use of steroids when fluid resuscitation and vasopressors are not effective in correcting hemodynamic instability, but this remains a weak recommendation [2]. The two recent RCTs evaluating the use of hydrocortisone in septic shock patients suggested conflicting results leaving clinicians with no explicit guidance [13-14]. There have been...
no meta-analysis to date which only utilized RCTs for systematic review and meta-analysis. The earlier systematic reviews have used studies, which had a variable patient population with systemic inflammatory response syndrome, sepsis, or septic shock. Those meta-analysis included RCTs, non-randomized trials, observational retrospective, and prospective studies and studies from the 1980s and 1990s where they also used dexamethasone, prednisone, and methylprednisone instead of only potent mineral corticoids, which are hydrocortisone and fludrocortisone. They also included studies in which steroids were used for reasons other than septic shock (e.g., meningitis). Our meta-analysis only incorporates RCTs, which included patients only with septic shock and utilized hydrocortisone alone or with fludrocortisone. Recently published RCTs in The New England Journal of Medicine (NEJM) on March 1, 2018, have not been part of any of the prior systematic reviews and meta-analyses, and the editorial published in the same edition of NEJM recommended to decide about patient management on the basis of subsequent meta-analyses utilizing these two RCTs [15].

Materials And Methods
We conducted this meta-analysis is to identify the effect of potent mineralocorticoids (hydrocortisone and fludrocortisone) in refractory septic shock patients with possible underlying adrenal and mineral corticoid insufficiency and their impact on short-term (defined as 28-day) mortality. The other steroids lack significant mineral corticoid activity as compared to hydrocortisone and fludrocortisone. For the primary outcome, we also performed the sub-group analysis by time to administration of hydrocortisone from time to randomization (early, i.e., within eight hours of randomization vs. late, i.e., within 24-72 hours of randomization). Our secondary outcomes assessed the long-term survival with the intensive care unit (ICU) and the hospital mortality and length of stay (LOS) with reversal of shock. We also evaluated the difference in commonly encountered complications of septic shock, including the incidence of superinfections and limb and cerebral ischemic events.

We completed a systematic review according to the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) guidelines [16]. We searched the MEDLINE and PubMed databases from inception until March 01, 2018, only for RCTs, comparing the use of hydrocortisone to the placebo in septic shock patients.

Our search strategy included (glucocorticoid OR hydrocortisone OR steroid) AND (sepsis OR septic OR septic shock). We used the Boolean operator ‘OR’ to combine the search terms.

Inclusion criteria
1) Prospective RCTs, 2) Comparing hydrocortisone with or without fludrocortisone to placebos in patients with documented septic shock, 3) Patients age ≥ 18 years, 4) At least 100 patients were randomized in the study, and 5) At least one endpoint was 28-day mortality.

Exclusion criteria
We excluded non-randomized and retrospective studies, studies which used steroids other than hydrocortisone, and total number of patients was <100; studies that included patients with sepsis and severe sepsis, were in the non-English language, lacked 28-day mortality data, and in which both arms received hydrocortisone.

Primary endpoints
The primary endpoint was mortality at 28 days.

Secondary endpoints
We analyzed the following secondary endpoints: 1) Mortality in ICU; 2) Mortality in the hospital; 3) Mortality at 90 days; 4) Mortality at one year; 5) Reversal of Shock; 6) ICU LOS; 7) Hospital LOS; 8) Incidence of limb and/or cerebral ischemia; and 9) Incidence of superinfection.

Data extraction and quality assessment
Four reviewers, W.J.S., A.R., U.A.S., and M.O.H. extracted the data in the predefined data fields in the Excel sheet for baseline characteristics and study outcomes. They added outcomes that were mentioned in the outcomes tables and described in the text. W.J.S. cross-checked all the entered data and made corrections where necessary. All four reviewers agreed with the corrections and the final entry. Table 1 shows the features and differences of individual RCTs, and Table 2 summarizes the baseline characteristics of individual trials [9,11-14,17]. We used Cochrane collaboration’s tool risk assessment of bias in randomized trials for the quality assessment of RCTs [18] (Figures 1-2 and Table 3).
| Outcome                                             | Effect Estimate | Confidence Interval             | p-value | I² (%) |
|-----------------------------------------------------|-----------------|---------------------------------|---------|--------|
| **Primary Outcome**                                 |                 |                                 |         |        |
| Mortality at 28 days                                | 0.92            | 0.85 – 0.99                     | 0.04    | 0      |
| **Secondary Outcomes**                              |                 |                                 |         |        |
| Mortality in Intensive Care Unit After sensitivity analysis | 0.93 0.87       | 0.81 - 1.08 0.78 – 0.97         | 0.35 0.01 | 52 0   |
| Mortality in the hospital                           | 0.95            | 0.84 – 1.08                     | 0.41    | 39     |
| Mortality at 90 days                                | 0.93            | 0.84 – 1.02                     | 0.13    | 37     |
| Mortality at one year                               | 0.97            | 0.84 – 1.12                     | 0.67    | 46     |
| Reversal of Shock                                   | 1.17            | 0.74 – 1.86                     | 0.5     | 24     |
| Intensive Care Unit Length of Stay                  | 0.89            | -2.56 to 4.33                   | 0.61    | 0      |
| Hospital Length of Stay                             | 1.58            | -4.23 to 7.38                   | 0.59    | 0      |
| The incidence of Superinfection                     | 1.15            | 1.04 – 1.27                     | 0.008   | 0      |
| The incidence of limb and/or cerebral ischemia      | 1.32            | 0.30 – 5.90                     | 0.72    | 0      |

**TABLE 1: Outcomes**
| Name                                      | Design                                  | Country                      | Publication Year | Journal   | Enrollment | Population              | Time to randomization from the onset of shock | Setting | Intervention Vs. Comparison | Dose and Type of Steroid and Route of Administration | F/u Duration |
|-------------------------------------------|-----------------------------------------|------------------------------|------------------|-----------|------------|--------------------------|-----------------------------------------------|---------|----------------------------|--------------------------------------------------|--------------|
| 2018 APROCCHSS trial [14]                | Double-blind placebo-controlled RCT     | France                       | 3/1/18           | NEJM      | September 2008- June 2015 | Septic shock                          | Within 24 hours of onset of shock                      | ICU     | Hydrocortisone plus Fludrocortisone vs. Placebo | 50 mg IV Q6 hours plus 50 µg 9-α-fludrocortisone via NG tube for 7 days w/o tapering | 180 days     |
| 2018 ADRENAL trial [13]                  | Double-blind placebo-controlled RCT     | UK, NZ, KSA, Australia, Denmark | 1/15/18          | NEJM      | March 2013- April 2017    | Septic shock                          | Within 24 hours of onset of shock                      | ICU     | Hydrocortisone vs. Placebo                   | 200 mgid as a continuous IV Infusion for 7 days                                      | 90 days      |
| 2017 Qingquan Lv et al. [11]             | Double-blind placebo-controlled RCT     | China                        | 6/4/17           | AJEM      | September 2015 - September 2016 | Septic shock                          | Within 6 hours of onset of shock                      | ICU     | Hydrocortisone vs. Placebo                   | 200 mgid as a continuous IV Infusion for 6 days, then tapered during a 6-day period                                      | 28 days      |
| 2008 CORTICUS trial [17]                 | Double-blind placebo-controlled RCT     | Austria, Israel, Belgium, UK, Germany, France, Portugal, Netherlands | 1/10/08          | NEJM      | March 2002- November 2005 | Septic shock                          | Within 72 hours of onset of shock                      | ICU     | Hydrocortisone vs. Placebo                   | 50 mg IV Q6 hours for 5 days; then tapered during a 6-day period                                      | 28 days      |
| 2002 Annane et al. [9]                   | Double-blind placebo-controlled RCT     | France                       | 8/21/02          | JAMA      | September 1995 - March 1999 | Septic shock                          | Within 8 hours of onset of shock                      | ICU     | Hydrocortisone plus Fludrocortisone vs. Placebo | 50 mg IV Q6 hours plus 50 µg 9-α-fludrocortisone via NG tube for 7 days w/o tapering                                      | 28 days      |

**TABLE 2: Characteristics of Randomized Control Trials**

RCT = Randomized Control Trial, F/u = Follow up, n. = number, NEJM = New England Journal of Medicine AJEM: American Journal of Emergency Medicine. JAMA: Journal of the American Medical Association, NZ: New Zealand, KSA: Kingdom of Saudi Arabia, UK: United Kingdom; ICU: Intensive Care Unit; IV = intravenous, w/o = without
FIGURE 1: PRISMA 2009 Study Search and Selection Diagram

PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses

FIGURE 2: Primary Outcome Mortality at 28-Days

| Study or Subgroup | Hydrocortisone Events | Total | Placebo Events | Total | Risk Ratio | M-H, Random, 95% CI | Risk Ratio | M-H, Random, 95% CI |
|-------------------|-----------------------|-------|----------------|-------|------------|---------------------|------------|---------------------|
| 1.1.1 Within 8 hours of onset of shock |                       |       |                |       |            |                     |            |                     |
| 2002 Annane et al. | 82                    | 150   | 91 149         | 161   | 0.90 (0.74, 1.10) |                     |            |                     |
| 2017 Geng-quan Lu et al. | 23    | 58    | 19 60         | 79    | 1.25 (0.77, 2.04) |                     |            |                     |
| Subtotal (95% CI)  | 208                   | 398   | 109 219       | 328   | 0.89 (0.73, 1.08) |                     |            |                     |
| Total events       | 105                   | 110   |                |       |            |                     |            |                     |

Test for overall effect: Z = 0.12 (P = 0.90)

| 1.1.2 Within 24 to 72 hours of the onset of shock |                       |       |                |       |            |                     |            |                     |
| 2008 CORTICUS Trial | 86                    | 251   | 78 248       | 326   | 1.09 (0.85, 1.40) |                     |            |                     |
| 2018 ADRENAL Trial  | 410                   | 1641  | 448 1690     | 5128  | 0.91 (0.81, 1.03) |                     |            |                     |
| Subtotal (95% CI)   | 497                   | 2090  | 526 2218     | 5500  | 0.92 (0.86, 1.01) |                     |            |                     |
| Total events        | 703                   | 770   |                |       |            |                     |            |                     |

Test for overall effect: Z = 1.69 (P = 0.09)

| Total (95% CI)      | 2014                  | 2904  | 100.00%       |       | 0.92 (0.85, 0.99) |                     |            |                     |
| Total events        | 828                   | 830   |                |       |            |                     |            |                     |

Test for overall effect: Z = 2.03 (P = 0.04)
Test for autonomous differences: CH = 0.17, df = 1 (P = 0.08), P = 0%
| Studies                                | 2018 APROCCHSS trial [14] | 2018 ADRENAL trial [13] | 2017 Qingquan Lv et al. [11] | 2008 CORTICUS trial [17] | 2002 Annane et al. [9] |
|----------------------------------------|---------------------------|--------------------------|-------------------------------|---------------------------|------------------------|
| Treatment arms                         | Hydrocortisone + Fludrocortisone | Placebo | Hydrocortisone | Placebo | Hydrocortisone | Placebo | Hydrocortisone + Fludrocortisone | Placebo |
| N                                      | 614| 627| 1853| 1860| 58| 60| 251| 248| 150| 149|
| Male sex — no. (%)                     | 402 (65.5) | 424 (67.7) | 1119 (60.4) | 1140 (61.3) | 33 (56.9) | 37 (61.7) | 166 (66) | 166 (67) | 96 (64) | 104 (70) |
| Age — years Mean ± SD                  | 66±14 | 66±15 | 62.3±14.9 | 62.7±15.2 | 68.8±12.6 | 64.8±16.7 | 63±14 | 63±15 | 62(15) | 60(17) |
| Whites - no. (%)                       | N/A | N/A | N/A | N/A | N/A | N/A | 236 (94) | 228 (92) | 137 (92) | 139 (95) |
| Admissions from Medical Ward no. (%)   | 495 (82.4) | 499 (81) | 1273 (68.8) | 1266 (68.2) | 17 (41.5) | 22 (57.9) | 80 (32) | 93 (38) | 89(59) | 90(60) |
| Admissions from Surgery No. (%)        | N/A | N/A | 576 (31.2) | 591 (31.8) | N/A | N/A | 169 (67.8) | 153 (62) | 61(40.7) | 59(39.6) |
| SAPS II                                | 56±19 | 56±19 | N/A | N/A | N/A | N/A | 49.5±17.8 | 48.6±16.7 | 60(19) | 57(19) |
| SAPS III                               | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| APACHE II Score Mean ± SD              | N/A | N/A | 12±3 | 11±3 | N/A | N/A | 11.9±3.3 | 9.9±3.0 | 10.6±3.4 | 10.6±3.2 | N/A |
| SOFA Score Mean ± SD                   | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SIRS Criteria, No. /Total no. (%)      | Temperature ≤36 °C or ≥ 38 °C | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Temperature °C                         | N/A | N/A | N/A | N/A | N/A | N/A | 37.9±1.5 | 38.0±1.4 | 38.0±2 | 37.9±2.2 |
| Heart rate Mean ± SD or > 90 beats/min | N/A | N/A | 95±21.6 | 95±20.9 | N/A | N/A | 119±26 | 118±25 | 118±21 | 118±21 |
| Mean arterial pressure — mm Hg         | N/A | N/A | 72.5±8.2 | 72.2±8.3 | N/A | N/A | N/A | N/A | 54±10 | 55±10 |
| Systolic Blood Pressure - mm Hg        | N/A | N/A | N/A | N/A | N/A | N/A | 94±23 | 95±27 | N/A | N/A |
| Central venous pressure — mm Hg        | N/A | N/A | 12.0±5.2 | 12.1±5.3 | N/A | N/A | N/A | N/A | N/A | N/A |
| Lowest mean arterial pressure — mm Hg  | N/A | N/A | 57.3±8.5 | 57.1±9.1 | N/A | N/A | N/A | N/A | N/A | N/A |
| Highest lactate level — mg/dl          | N/A | N/A | 34.2±29.1 | 34.5±29.2 | N/A | N/A | 3.9±3.6 | 4.1±4.1 | 4.6±4.4 | 4.3±4.3 |
| Highest                               | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
|                         | N/A | N/A | 1.7±2.4 | 1.7±2.4 | N/A | N/A | N/A | N/A | N/A |
|-------------------------|-----|-----|---------|---------|-----|-----|-----|-----|-----|
| Bilirubin level — mg/dl |     |     |         |         |     |     |     |     |     |
| Highest creatinine level — mg/dl | N/A | N/A | 2.2±2.0 | 2.1±1.7 | N/A | N/A | N/A | N/A | N/A |
| Lowest Pao2:Fio2 | N/A | N/A | 164.6±91.3 | 166.4±91.9 | N/A | 162±89 | 154±73 | 178±120 | 171±124 |
| Highest white-cell count — cells ×10−9/liter | N/A | N/A | 17.4±11.4 | 17.8±14.7 | N/A | N/A | N/A | N/A | N/A |
| Leukocytosis, leukopenia, left shift | N/A | N/A | 54 (93.1) | 49 (81.7) | N/A | N/A | N/A | N/A | N/A |
| Patients with comorbidities, no. (%) | N/A | N/A | 25 (43.1) | 26 (43.3) | 89 (35) | 98 (40) | 44 (29) | 40 (27) |
| Hypertension | N/A | N/A | 2 (3.4) | 4 (6.7) | 27 (11) | 29 (12) | 17 (11) | 24 (16) |
| COPD | N/A | N/A | 7 (12.1) | 8 (13.3) | 37 (15) | 47 (19) | 20 (13) | 11 (7) |
| DM | N/A | N/A | 14 (24.1) | 12 (20.6) | 51 (20) | 56 (23) | 20 (13) | 17 (11) |
| CKD | N/A | N/A | 2 (3.4) | 1 (1.7) | 22 (9) | 21 (9) | N/A | N/A |
| Malignancy | N/A | N/A | 9 (15.5) | 13 (21.7) | 47 (19) | 37 (15) | 23 (15) | 18 (12) |
| Community Acquired Infection | 468 (77.7) | 459 (75.5) | N/A | N/A | N/A | N/A | N/A | 94 (63) | 93 (62) |
| Nosocomial, ICU | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Nosocomial, Ward | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Nosocomial | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 30 (20) | 34 (23) |
| Site of Infection no. (%) |     |     |         |         |     |     |     |     |     |
| Unknown | 11 (1.8) | 18 (2.9) | 145 (7.9) | 136 (7.3) | 7 (12.1) | 4 (6.1) | N/A | N/A | 2 (1) |
| Lung | 373 (60.7) | 363 (58) | 623 (33.8) | 677 (36.5) | 22 (37.9) | 22 (36.7) | N/A | N/A | 61 (41) |
| Abdomen | 74 (12.1) | 68 (10.9) | 477 (25.9) | 467 (25.2) | 21 (36.2) | 34 (56.7) | N/A | N/A | 26 (17) |
| Urinary Tract | 102 (16.6) | 118 (18.8) | 146 (146.7) | 133 (7.2) | 10 (17.2) | 7 (11.7) | N/A | N/A | 7 (5) |
| Skin and soft tissues | N/A | N/A | 137 (7.4) | 116 (6.3) | 2 (3.4) | 1 (1.7) | N/A | N/A | 8 (5) |
| Bacteremia | N/A | N/A | N/A | 18 (31.0) | 13 (21.7) | N/A | N/A | 39 (26) | 31 (21) |
| Surgical wound | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Positive blood culture no. (%) | 225 (36.6) | 229 (36.6) | 316 (1.1) | 325 (17.5) | 42 (72.4) | 44 (73.3) | N/A | N/A | 39 (26) |
| Documented pathogen no. (%) | 450 (73.3) | 441 (70.4) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gram-positive bacteria no. (%) | 235 (38.3) | 228 (36.4) | N/A | N/A | 4 (6.9) | 4 (6.7) | N/A | N/A | 46 (31) |

2019 Siddiqui et al. Cureus 11(6): e4914. DOI 10.7759/cureus.4914
| Gram-negative bacteria no. (%) | Adequate antimicrobial therapy no. (%) | Vasopressor administration | Epinephrine | Norepinephrine | Glucocorticoids | Mechanical ventilation no. (%) | Renal-replacement therapy no. (%) | Organ failure n. (%) | Respiratory | Liver | Renal | Coagulation | Microcirculatory | Central nervous system |
|-------------------------------|--------------------------------------|---------------------------|-------------|---------------|----------------|-----------------------------|-----------------------------|----------------------|-------------|--------|--------|-----------|---------------|-------------------|
| 261 (42.5) | 595 (96.9) | 261 (42.5) | 595 (96.9) | 26 (44.9) | 1817 (98.3) | 534 (92.3) | 161 (27) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 264 (42.2) | 595 (96.2) | 264 (42.2) | 595 (96.2) | 48 (82.8) | 1821 (98.1) | 569 (91.3) | 168 (28.1) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| N/A | 1817 (98.3) | N/A | 1845 (99.8) | N/A | 52 (89.7) | 228 (92.3) | 228 (12.3) | N/A | N/A | N/A | N/A | N/A | N/A |
| 26 (44.9) | 48 (82.8) | 26 (44.9) | 52 (89.7) | 18 (30.0) | 51 (85.0) | 26 (44.9) | 242 (13.0) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 31 (51.7) | 47 (78.3) | 31 (51.7) | 51 (85.0) | 18 (30.0) | 42 (67.7) | 31 (51.7) | 24 (41.4) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 4 (6.7) | 1 (1.7) | 1 (1.7) | 1 (1.7) | N/A | N/A | N/A |
| 37 (25) | 137 (91) | 37 (25) | 228 (92.3) | 3 (5.2) | 1 (1.7) | 37 (25) | 18 (30.0) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 45 (30) | 141 (95) | 45 (30) | 26 (44.9) | N/A | N/A | 45 (30) | 24 (41.4) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

**TABLE 3: Baseline Characteristics of Individuals Trials**

no. = Number; SD = Standard Deviation; SAPS = Simplified Acute Physiology Score; SOFA = Sequential Organ Failure Assessment; APACHE = Acute Physiology and Chronic Health Evaluation; SIRS = Systemic Inflammatory Response Syndrome; PaO2:FiO2 = the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen; COPD = Chronic Obstructive Pulmonary Disease; CAD = Coronary Artery Disease; DM = Diabetes Mellitus; CKD = Chronic Kidney Disease; ICU = Intensive Care Unit; IV = Intravenous; N/A = Data not available

---

**Data synthesis and analysis**

*Statistical Method*
We used a random effects model for our statistical analysis in RevMan Version 5.3 Copenhagen. We used the Mantel-Haenszel method for the statistical analysis of dichotomous data to calculate the risks ratio and inverse variance for the continuous data to estimate the mean difference. We reported our results using the effect estimate with 95% confidence interval. A two-sided p-value of ≤ 0.05 was considered statistically significant.

**Heterogeneity**

We used I² and Chi² statistics to estimate the heterogeneity with RevMan Version 5.3 Copenhagen. Variability between studies (inter-study) compared to variability within studies (intra-study) was assessed with the I² statistic; I² >50% indicates substantial heterogeneity as mentioned in the Cochrane Handbook for Systematic Reviews for Interventions, Version 5.1.0, Part 2: General Methods for Cochrane Reviews [19]. We performed a sensitivity analysis for substantial heterogeneity.

**Study Selection**

We identified 244 citations for RCTs. Two reviewers W.J.S. and P.I. reviewed the abstracts of each study and selected 25 articles and reviewed their full papers. They excluded 20 papers and selected five articles for qualitative and quantitative analysis comparing hydrocortisone to the placebo in patients with septic shock. Figure 1 shows the PRISMA study flow diagram and Table 4 summarizes the excluded studies failing to meet the inclusion criteria.

| Name                     | Random Sequence                        | Allocation Concealment | Blinding of Participants and Personnel | Blinding of Outcome Assessment | Incomplete Outcome Data | Selective Reporting |
|--------------------------|----------------------------------------|------------------------|----------------------------------------|-------------------------------|-------------------------|---------------------|
| 2018 APROCCHSS trial [14]| Yes Via Centralized Randomization Web site, stratified using permutation blocks Low Risk | Yes Low Risk            | Yes Low Risk                           | Yes Low Risk                  | No Low Risk             | No Low Risk         |
| 2018 ADRENAL trial [13]  | Yes Password-protected, encrypted, Web-based Interface Low Risk | Yes Low Risk            | Yes Low Risk                           | Yes Low Risk                  | No Low Risk             | No Low Risk         |
| 2017 Qingquan Lv et al. [11] | Yes Computer-generated random numbers Low Risk | Not Reported Unclear   | Yes Low Risk                           | Not Reported Unclear          | No Low Risk             | No Low Risk         |
| 2008 CORTICUS trial [17] | Yes Computerized random-number generator Low Risk | Yes Low Risk            | Yes Low Risk                           | Yes Low Risk                  | Yes High Risk           | No Low Risk         |
| 2002 Annane et al. [9]   | Yes Computer-generated random number Low Risk | Yes Low Risk            | Yes Low Risk                           | Yes Low Risk                  | Yes One person withdrew consent after getting assigned treatment was excluded from analysis High Risk | No Low Risk         |

**TABLE 4: Cochrane Risk of Bias for Quality Assessment**

**Qualitative Analysis**

We included five RCTs with 5,838 patients in our analysis. 2,914 patients were randomized to the hydrocortisone arm vs. 2,924 to the placebo arm. Two studies used Fludrocortisone in addition to hydrocortisone in the steroid arm [9,14]. (Table 5)
### Results

**Primary endpoints**

See Table 1.

**Mortality at 28 Days**

There was a total of 1,688 deaths with a significantly reduced number of deaths in the hydrocortisone and fludrocortisone arm as compared to the placebo arm. There were 808 deaths in the hydrocortisone arm vs. 880 in the placebo arm, risk ratio (RR) = 0.92, confidence interval (CI) = 0.85 - 0.99, p = 0.04, I² = 0 %, suggesting the mortality benefit at 28 days with hydrocortisone and fludrocortisone in septic shock patients. The sub-group analysis of the early administration of hydrocortisone, i.e., within eight hours of randomization showed no difference between the two groups, 105 in hydrocortisone group vs. 110 in the placebo arm, RR = 0.98, CI = 0.73 - 1.32, p = 0.90, I² = 38%. The sub-group analysis of the late administration of hydrocortisone, i.e., within 24-72 hours of randomization showed a non-significant trend towards decreased mortality in the hydrocortisone arm, 703 vs. 770 in the placebo arm, RR = 0.92, CI = 0.83 - 1.01, p = 0.09, I² = 16% (Figure 2).

**Secondary endpoints**

See Table 1.

**Mortality in the ICU**

There was a total of 856 deaths in the ICU with no difference in the number of deaths between the two groups, the hydrocortisone arm (409) vs. the placebo arm (447), RR = 0.93, CI = 0.81-1.08, p = 0.35, I² = 52% (Figure 3). There was substantial heterogeneity between the two groups. On running the sensitivity analysis without the results of the Corticosteroid Therapy of Septic Shock (CORTICUS) trial, the results became statistically significant favoring hydrocortisone and fludrocortisone with I² reducing to 0%. Hydrocortisone arm = 307 vs. placebo arm = 358 RR = 0.87, CI = 0.78-0.97, p = 0.01, I² = 0%.

**Mortality in the Hospital**

There were a total of 974 deaths during the hospital stay with no difference in either arm, 468 in the...
hydrocortisone arm vs. 506 in the placebo arm, RR = 0.95, CI = 0.84 - 1.08, p = 0.41, I² = 39% (Figure 4).

Two trials reported 90-day mortality. There was a non-significant trend towards decreased mortality at 90 days in the hydrocortisone and fludrocortisone group, 775 vs. 834 in the placebo arm, RR = 0.93, CI = 0.84-1.02, p = 0.13, I² = 37% (Figure 5).

Two studies reported one-year mortality. There was no difference in mortality between the two groups at one year, 239 deaths in each arm, RR = 0.97, CI = 0.84-1.12, p = 0.67, I² = 46% (Figure 6).

Two studies reported the shock reversal outcome. A total of 238 patients in the hydrocortisone group had shock reversal as compared to 226 in the placebo arm. There was no statistical difference between the two
groups, OR = 1.17, CI = 0.74-1.86, p = 0.50, I² = 24% (Figure 7).

**FIGURE 7: Forest Plot Showing Mortality at 90 Days**

**ICU LOS**

Only two studies reported the ICU LOS. There was no difference in the LOS in the ICU between the two groups, point estimate = 0.89 days, CI = -2.56 to 4.33, p = 0.61, I² = 0% (Figure 8).

**FIGURE 8: Forest Plot Showing Mortality at One Year**

**Hospital LOS**

Two studies reported the LOS in the hospital. No statistical difference was observed in the two arms, point estimate = 1.58 days, CI = -4.23 to 7.38, p = 0.59, I² = 0% (Figure 9).

**FIGURE 9: Forest Plot Showing Reversal of Shock**

**Incidence of Limb and/or Cerebral Ischemia**

Two studies reported the incidence of either limb and/or cerebral ischemia. There was no difference in the two groups, four in the hydrocortisone arm as compared to three in the placebo arm, RR = 1.32, CI = 0.30-5.9, p = 0.72, I² = 0% (Figure 10).

**FIGURE 10: Forest Plot Showing the Length of Stay in the Intensive Care Unit**

**Incidence of Superinfection**

Three studies reported the incidence of superinfection in the two treatment arms. Hydrocortisone was associated with a significantly higher number of superinfections as compared to placebo, 436 vs. 385, RR =
1.15, CI = 1.04-1.27, p = 0.008, I² = 0% (Figures 11-13).

**FIGURE 11:** Forest Plot Showing the Length of Stay in the Hospital

**FIGURE 12:** Forest Plot Showing the Incidence of Limb and/or Cerebral Ischemia

**FIGURE 13:** Forest Plot Showing the Incidence of Superinfections

**Discussion**

The use of steroids in septic shock patients remains controversial due to the inconsistent results of previous trials and meta-analyses. Some authors believe that the significant variation in results could be due to dosing, duration of administration, and timing of initiation of steroids [20-21]. In pre-1997 trials, steroids were used in higher doses for a shorter duration. Subsequent studies were done after 1997 used steroids in physiological doses but for a longer duration, i.e., seven days. In the landmark study by Annane et al., steroids were started within three to eight hours after the diagnosis of septic shock, which led to a significant reduction in mortality [9]. However, in the CORTICUS trial, steroids were started within 12 hours of diagnosis, and no mortality benefit was observed [17]. Nonetheless, both of these trials showed an early reversal of shock in the steroid group. Due to the controversies surrounding the timing of steroid use noted in previous studies, Qing-Quan Lv et al. initiated steroids at the same time when vasopressors were started and found that reversal of shock was similar in both groups and there was no mortality difference either [11]. In the two recent landmark trials, ADRENAL (Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock) and APROCCHSS (Activated Protein C and Corticosteroids for Human Septic Shock), steroids were started four and six hours after the initiation of vasopressors. Both trials also showed a reduction in pressor requirement with the use of steroids. Another point of debate has been regarding continuous infusion versus intermittent bolus dosing. The HYPRESS (Hydrocortisone for Prevention of Septic Shock) trial, which randomized patients with severe sepsis before developing septic shock, studied the continuous infusion of hydrocortisone with a taper over six days. It also failed to uncover any significant mortality benefit nor did it prevent the development of septic shock [12]. However, the surviving sepsis campaign guidelines recommend only intermittent bolus doses of hydrocortisone and not continuous infusion [2].

Amidst all this confusion, recently, two large multicenter RCTs were published to confirm or refute the findings of previous studies. In the ADRENAL trial, nearly 3,800 patients were randomized and assigned to receive a continuous infusion of either hydrocortisone or placebo. This study was adequately powered to determine a mortality difference [13]. In the APROCCHSS trial, a total of 1,241 patients were randomized to receive either a hydrocortisone - fludrocortisone combination or placebo [14]. The primary outcome in both trials was mortality at 90 days. The ADRENAL trial showed no significant mortality benefit at 90 days; on the other hand, in the APROCCHSS trial, a mortality benefit was noted in the hydrocortisone and fludrocortisone group. Both trials did show an early reversal of shock and rapid cessation of mechanical ventilation, which was similar to the results of earlier studies [9,17].
A review of these trials provides some additional insights into the subsets of patients who might benefit from the addition of corticosteroid therapy on top of conventional treatment for sepsis. The RCT with lower overall mortality (HYPRESS) had no mortality benefit, likely due to less sick patients (severe sepsis vs. septic shock) [12], and the trials with the highest mortality (French, APPROCHSS) likely with the sickest patients, showed a mortality benefit [9,14]. This suggests that the addition of steroids may be helpful in patients who are "sicker," and, in this case, unresponsive to conventional therapy of fluids, vasopressors, and antibiotics. Additionally, in the ADRENAL trial, there was a mortality benefit in the sub-group that received steroids after the first six hours, before which the patient, otherwise responsive to conventional goal-directed therapy, would be "selected out," leaving patients who may have an additional benefit from corticosteroid therapy. Similarly, our sub-group analysis of the primary outcome on the basis of time to administration of hydrocortisone from randomization suggested a strong trend towards reduced mortality in the late administration group as compared to the early administration group (within eight hours vs. within 24 to 72 hours). Since the trials in the late administration group may also have patients who received hydrocortisone within eight hours of randomization could have led to a non-significant trend towards decreased mortality. These observations would remain speculative in the absence of a randomized trial looking at these specific outcomes and warrant a randomized clinical trial looking at hydrocortisone use in patients who are unresponsive to early goal-directed therapy. Such a trial would indeed be challenging to design and implement, given logistic and ethical issues.

Our study noted a statistically significant mortality benefit of the primary outcome of mortality at 28 days in the hydrocortisone group as compared to placebo. Also, there was a non-significant reduction in ICU mortality in the hydrocortisone arm, which became statistically significant after sensitivity analysis. This finding also suggests that the use of hydrocortisone incurs a mortality benefit in the ICU setting in addition to 28 days. However, the rates of superinfection were noted to be higher in the hydrocortisone group as compared to the placebo, which is consistent with the results of individual trials and older studies. The strength of our analysis primarily lies in study selection. We included only RCTs, which included patients with a septic shock, which compared hydrocortisone to placebo, and studies with at least a hundred patients in the trial. This is in contrast to earlier meta-analyses, which also included non-RCTs, cohort and retrospective studies, and studies with small population sizes with different steroids, including methylprednisolone, dexamethasone, betamethasone, hydrocortisone, and prednisone [10,20].

The limitations in performing this meta-analysis are: we included trials ranging from 2002 up until now. The management of sepsis and septic shock has evolved since early 2000, and so have the surviving sepsis guidelines [2,22-25], which is evident by the reduction in mortality from 57.8% in the French study [9] to 23.3% to 35.8% in subsequent studies [11,15-14,17]. Two out of five trials included fludrocortisone in addition to hydrocortisone. The recommendations from the American College of Critical Care Medicine and the surviving sepsis campaign in 2008 have reported that hydrocortisone has enough mineralocorticoid effects, making the administration of fludrocortisone irrelevant. Thus, we believe that the addition of fludrocortisone could not have provided a significant benefit to influence the results of our study [22,25].

The last limitation was the way steroids were administered in individual RCTs, bolus vs. continuous infusion.

Conclusions

Our analysis showed a significant reduction in mortality at 28 days and a non-significant trend in ICU mortality and mortality at 90 days in the hydrocortisone group. The rates of superinfection were noted to be significantly higher in the hydrocortisone group. We believe there is still controversy over hydrocortisone, and we don’t know which patients, if any, should receive the drug. In the future, large RCTs are required before any new recommendations can be made comparing hydrocortisone to placebo, hydrocortisone plus fludrocortisone to placebo, and hydrocortisone to hydrocortisone plus fludrocortisone. Another potential trial can be designed comparing the time from the development of septic shock to the administration of hydrocortisone.

Additional Information

Disclosures

Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors declare that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Gaieski DF, Edwards JM, Kallan MJ, Carr BG: Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2015, 41:1167-1174. 10.1097/CCM.0000000000000819
2. Rhodes A, Evans LE, Alhazzani W, et al.: Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2016. Intensive Care Med. 2017, 43:304-377. 10.1007/s00134-017-4685-6
5. Yildiz O, Doganay M, Aygün B, Guven M, Kelestimur F, Tutus A: Physiological-dose steroid therapy in sepsis [ISRCTN62553588]. Crit Care. 2002, 6;251. 10.1186/cc1498

4. Bolhaar PE, Charpentier C, Levy B, Debourdeau M, Audibert G, Larcan A: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998, 26:645-650. 10.1097/00003246-199804000-00010

5. Schumer W: Steroids in the treatment of clinical septic shock. Ann Surg. 1976, 184:333-341.

6. Sprung CL, Caralis PV, Marcial EH, et al.: The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. New Eng J Med. 1984, 311:1137-1145. 10.1056/NEJM198411013111101

7. Lefering R, Neugebauer EA: Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995, 23:1294-1305. 10.1097/00003246-199507000-00021

8. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ Jr: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995, 23:1430-1439.

9. Annane D, Sebille V, Charpentier C, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002, 288:862-871. 10.1001/jama.288.7.862

10. Volbeda M, Wetersies J, Gluud C, Zijlstra G, van der Horst IC, Keus F: Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2015, 41:1220-1234. 10.1007/s00134-015-3899-6

11. Lv QG, Gu XH, Chen QH, Yu IQ, Zheng RQ: Early initiation of low-dose hydrocortisone treatment for septic shock in adults: A randomized clinical trial. The Am J Emerg Med. 2017, 35:1810-1814. 10.1016/j.ajem.2017.06.004

12. Keh D, Trips E, Marx G, et al.: Effect of hydrocortisone on development of shock among patients with severe sepsis: the HTPRESS randomized clinical trial. JAMA. 2016, 316:1775-1785. 10.1001/jama.2016.14799

13. Venkatesh B, Finfer S, Cohen J, et al.: Adjunctive glucocorticoid therapy in patients with septic shock. New Eng J Med. 2018, 378:797-808. 10.1056/NEJMoa1705835

14. Annane D, Renault A, Brun-Buisson C, et al.: Hydrocortisone plus fludrocortisone for adults with septic shock. New Eng J Med. 2018, 378:809-818. 10.1056/NEJMoa1705716

15. Suffredini AF: A role for hydrocortisone therapy in septic shock?. New Eng J Med. 2018, 378:860-861. 10.1056/NEJMra1801465

16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009, 339:2700. 10.1136/bmj.b2700

17. Sprung CL, Annane D, Keh D, et al.: Hydrocortisone therapy for patients with septic shock. New Eng J Med. 2008, 358:111-124. 10.1056/NEJMoa071366

18. Higgins JP, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136/bmj.d5928

19. Cochrane Handbook of Systematic Reviews of Interventions 5.1.0 Part 2: general methods for Cochrane Reviews. The Cochrane Collaboration 2011. (2011). https://training.cochrane.org/handbook.

20. Minnceni PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C: Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med. 2004, 141:47-56. 10.7326/0003-4819-141-1-200407060-00014

21. Katsenos CS, Antonopoulou AN, Apostolidou EN, Iakrimidou A, Kalpakou GT, Papanikolaou MN: Early administration of hydrocortisone replacement after the advent of septic shock: impact on survival and immune response. Crit Care Med. 2014, 42:1651-1657. 10.1097/CCM.0000000000000518

22. Dellingger RP, Levy MM, Carlet JM, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008, 36:296-327. 10.1097/01.ccm.0000316825.73481.1f

23. Dellingger RP, Carlet JM, Maurer H, et al.: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004, 32:858-873. 10.1097/01.ccm.0000134-004-2210-2

24. Dellingger RP, Levy MM, Rhodes A, et al.: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013, 41:580-637. 10.1097/CCM.0b013e31823b9a

25. Marik PE, Pastores SM, Annane D, et al.: Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008, 36:1957-1949. 10.1097/CCM.0b013e318176033a